<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01389102</url>
  </required_header>
  <id_info>
    <org_study_id>EST-01</org_study_id>
    <nct_id>NCT01389102</nct_id>
    <nct_alias>NCT00122200</nct_alias>
  </id_info>
  <brief_title>Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Estradiol Metered-Dose Transdermal Spray (MDTS) in the Treatment of Vasomotor Symptoms in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumara Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumara Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in
      postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind, placebo-controlled trial evaluating different doses of
      transdermal estradiol delivered by sray to symptomatic postmenopausal women. The endpoints
      are the reduction in frequency and severity of hot flushes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Patients completed a daily diary to record the number of mild, moderate and number of moderate or severe vasomotor symptoms [hot flushes and sweating] experienced each day.
Mild, moderate and severe hot flushes and sweating were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change the Severity of Moderate to Severe Vasomotor Symptoms</measure>
    <time_frame>baseline to week 12 (12 weeks)</time_frame>
    <description>Patients completed a daily diary to record the number of mild, moderate and severe vasomotor symptoms experienced each day.
Mild, moderate and severe were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity Severity of hot flushes was measured on a scale of none = 0, mild = 1, moderate = 2 and severe = 3.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">454</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Placebo transdermal three 90 μL sprays</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo transdermal two 90 μL sprays</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo transdermal one 90 μL spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol transdermal three 90 μL sprays</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol transdermal two 90 μL sprays</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol transdermal one 90 μL spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol transdermal one 90 μL spray</intervention_name>
    <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Estradiol transdermal one 90 μL spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol transdermal spray, two 90 μL sprays</intervention_name>
    <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Estradiol transdermal two 90 μL sprays</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol transdermal three 90 μL sprays</intervention_name>
    <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Estradiol transdermal three 90 μL sprays</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo transdermal two 90 μL sprays</intervention_name>
    <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Placebo transdermal two 90 μL sprays</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo transdermal three 90 μL sprays</intervention_name>
    <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Placebo transdermal three 90 μL sprays</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo transdermal one 90 μL spray</intervention_name>
    <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
    <arm_group_label>Placebo transdermal one 90 μL spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post menopausal women,

          -  Ages 35 or older,

          -  Frequent moderate to severe hot flushes,

          -  Qualifying general medical health

        Exclusion Criteria:

          -  Disqualifying gynecological disorders,

          -  Disqualifying dermatological disorders,

          -  Disqualifying concurrent conditions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Costal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Clinic</name>
      <address>
        <city>Oro Valley</city>
        <state>Arizona</state>
        <zip>85739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEA Womens Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Women's Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Speciality Care for Women</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento Research Medical Grp</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Steven Drosman</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta West Women's Center</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Ctr.</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Research</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic</name>
      <address>
        <city>Bismark</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriPhase Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG-South/OB-Gyn Health Ctr.</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Women's Medicine</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Eastern Virginia</name>
      <address>
        <city>Norfold</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Women's Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2011</study_first_posted>
  <results_first_submitted>February 29, 2012</results_first_submitted>
  <results_first_submitted_qc>June 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2012</results_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopause</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Polyestradiol phosphate</keyword>
  <keyword>Estradiol valerate</keyword>
  <keyword>Estradiol 3-benzoate</keyword>
  <keyword>Estradiol 17 beta-cypionate</keyword>
  <keyword>Estrogens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes</keyword>
  <keyword>Hormone Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 43 physicians' offices, or their affiliated locations, within the United States between 17 December 2004 and 09 March 2006</recruitment_details>
      <pre_assignment_details>Participants underwent a four week screening period to determine eligibility prior to assignment into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Transdermal Three 90 μL Sprays</title>
          <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="P2">
          <title>Placebo Transdermal Two 90 μL Sprays</title>
          <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="P3">
          <title>Placebo Transdermal One 90 μL Spray</title>
          <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="P4">
          <title>Estradiol Transdermal Three 90 μL Sprays</title>
          <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="P5">
          <title>Estradiol Transdermal Two 90 μL Sprays</title>
          <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="P6">
          <title>Estradiol Transdermal One 90 μL Spray</title>
          <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="74"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="61"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hurricane Katrina</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Traveling Out of Country</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unavailable due to husband's illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Judgement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Transdermal Three 90 μL Sprays</title>
          <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B2">
          <title>Placebo Transdermal Two 90 μL Sprays</title>
          <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B3">
          <title>Placebo Transdermal One 90 μL Spray</title>
          <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B4">
          <title>Estradiol Transdermal Three 90 μL Sprays</title>
          <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B5">
          <title>Estradiol Transdermal Two 90 μL Sprays</title>
          <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B6">
          <title>Estradiol Transdermal One 90 μL Spray</title>
          <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="77"/>
            <count group_id="B4" value="76"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="76"/>
            <count group_id="B7" value="454"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="6.3"/>
                    <measurement group_id="B2" value="52.0" spread="7.0"/>
                    <measurement group_id="B3" value="52.8" spread="6.9"/>
                    <measurement group_id="B4" value="52.3" spread="5.7"/>
                    <measurement group_id="B5" value="52.2" spread="6.8"/>
                    <measurement group_id="B6" value="53.5" spread="6.8"/>
                    <measurement group_id="B7" value="52.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day</title>
        <description>Patients completed a daily diary to record the number of mild, moderate and number of moderate or severe vasomotor symptoms [hot flushes and sweating] experienced each day.
Mild, moderate and severe hot flushes and sweating were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity</description>
        <time_frame>baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Transdermal Three 90 μL Sprays</title>
          </group>
          <group group_id="O2">
            <title>Placebo Transdermal Two 90 μL Sprays</title>
          </group>
          <group group_id="O3">
            <title>Placebo Transdermal One 90 μL Spray</title>
          </group>
          <group group_id="O4">
            <title>Estradiol Transdermal Three 90 μL Sprays</title>
          </group>
          <group group_id="O5">
            <title>Estradiol Transdermal Two 90 μL Sprays</title>
          </group>
          <group group_id="O6">
            <title>Estradiol Transdermal One 90 μL Spray</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day</title>
          <description>Patients completed a daily diary to record the number of mild, moderate and number of moderate or severe vasomotor symptoms [hot flushes and sweating] experienced each day.
Mild, moderate and severe hot flushes and sweating were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity</description>
          <units>Vasomotor symptoms per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.32" spread="6.30"/>
                    <measurement group_id="O2" value="-6.19" spread="5.77"/>
                    <measurement group_id="O3" value="-4.76" spread="5.84"/>
                    <measurement group_id="O4" value="-8.44" spread="4.50"/>
                    <measurement group_id="O5" value="-8.66" spread="6.65"/>
                    <measurement group_id="O6" value="-8.10" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0099</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change the Severity of Moderate to Severe Vasomotor Symptoms</title>
        <description>Patients completed a daily diary to record the number of mild, moderate and severe vasomotor symptoms experienced each day.
Mild, moderate and severe were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity Severity of hot flushes was measured on a scale of none = 0, mild = 1, moderate = 2 and severe = 3.</description>
        <time_frame>baseline to week 12 (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Transdermal Three 90 μL Sprays</title>
            <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
          <group group_id="O2">
            <title>Placebo Transdermal Two 90 μL Sprays</title>
            <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
          <group group_id="O3">
            <title>Placebo Transdermal One 90 μL Spray</title>
            <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
          <group group_id="O4">
            <title>Estradiol Transdermal Three 90 μL Sprays</title>
            <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
          <group group_id="O5">
            <title>Estradiol Transdermal Two 90 μL Sprays</title>
            <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
          <group group_id="O6">
            <title>Estradiol Transdermal One 90 μL Spray</title>
            <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change the Severity of Moderate to Severe Vasomotor Symptoms</title>
          <description>Patients completed a daily diary to record the number of mild, moderate and severe vasomotor symptoms experienced each day.
Mild, moderate and severe were defined as follows:
Mild = sensation of heat without sweating Moderate = sensation of heat with sweating, ability to continue activity Severe = sensation of heat with sweating, causing discontinuation of activity Severity of hot flushes was measured on a scale of none = 0, mild = 1, moderate = 2 and severe = 3.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.75"/>
                    <measurement group_id="O2" value="-0.54" spread="0.89"/>
                    <measurement group_id="O3" value="-0.26" spread="0.60"/>
                    <measurement group_id="O4" value="-1.07" spread="1.01"/>
                    <measurement group_id="O5" value="-0.92" spread="1.01"/>
                    <measurement group_id="O6" value="-1.04" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0406</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse Events will be collected and assessed during each study visit during the 12 week treatment period and any ongoing events will be followed until resolution or stabilization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Transdermal Three 90 μL Sprays</title>
          <description>Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="E2">
          <title>Placebo Transdermal Two 90 μL Sprays</title>
          <description>Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="E3">
          <title>Placebo Transdermal One 90 μL Spray</title>
          <description>Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="E4">
          <title>Estradiol Transdermal Three 90 μL Sprays</title>
          <description>Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="E5">
          <title>Estradiol Transdermal Two 90 μL Sprays</title>
          <description>Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
        <group group_id="E6">
          <title>Estradiol Transdermal One 90 μL Spray</title>
          <description>Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired Gastric Emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Airways Disease Excerbated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nipple Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator shall not publish, or seek to publish, either in whole or in part, any results of the Clinical Investigation without the written consent of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Joffrion</name_or_title>
      <organization>KV Pharmaceutical Company</organization>
      <phone>314-645-6600 ext 3410</phone>
      <email>jjoffrion@kvph.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

